TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT01720836: Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Sponsor: Olivera Finn · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 30 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT01720836 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT01720836 Rescue Dossier →